Name: Porphyria Treatment Market Size, Share, Growth and Report 2024-2031
Creator: DataM Intelligence
Published: Mon Nov 18 2024 21:36:22 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions
Keywords: Porphyria treatment market

Porphyria Treatment Market Size, Share, Growth and Report 2024-2031

Porphyria Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Porphyria Treatment Market is Segmented&nbsp;By Disease Type (Acute Porphyrias, and Cutaneous Porphyrias),&nbsp;By Diagnosis (Blood test,&nbsp;Urine test,&nbsp;Genetic test,&nbsp;Others),&nbsp;By Treatment (Medications,&nbsp;Phlebotomy, and Others),&nbsp;By End-user (Hospitals,&nbsp;Blood Centers,&nbsp;Others),&nbsp;By Distribution Channel (Hospital Pharmacies,&nbsp;Retail Pharmacies,&nbsp;Online Pharmacies,&nbsp;Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Analysis 2024-2031</h2>&nbsp;<h3>Market Overview</h3><blockquote>The global porphyria treatment market size is growing at a&nbsp;CAGR of 9.2% during the forecast period (2024-2031).&nbsp;</blockquote>A porphyria is a group of disorders caused by an over-accumulation of porphyrin, which helps hemoglobin, the protein that carries oxygen in the blood. Symptoms vary depending on the specific type. Acute porphyrias affect the nervous system and other organs. Cutaneous porphyrias primarily affect the skin. Possible treatments for porphyrias include avoiding triggers, taking medications to ease symptoms, delivering heme through a vein, or having blood extracted to lower iron in the body. Porphyria has no cure, although <a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/research-report/porphyria-treatment-market">porphyria treatments</a> are available depending on the type of sickness.As per DataM Intelligence, porphyria treatment market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global porphyria treatment market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Porphyria treatment market in the United States and Canada produces the utmost share. Whereas the European porphyria treatment market is projected to continue its presence globally during the period of 2022- 2029.<h3>Market Summary</h3><figure class="table"><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td>Metrics</td><td>Details</td></tr><tr><td>Market&nbsp;CAGR</td><td>9.2%</td></tr><tr><td>Segments Covered</td><td>By Usage,&nbsp;By Product,&nbsp;By Type,&nbsp;By Distribution Channel,&nbsp;By End Users,&nbsp;and By Region</td></tr><tr><td>Report Insights Covered</td><td>Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.</td></tr><tr><td>Fastest Growing Region</td><td>Asia Pacific</td></tr><tr><td>Largest Market Share&nbsp;</td><td>North America</td></tr></tbody></table></figure>To know more insights into the Market, Get Our&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/download-sample/n95-mask-market">Sample Brochure</a><h3>Market Dynamics</h3>Advancement in treating congenital Erythropoietic Porphyria is expected to drive market growth.The only curative therapeutic options for CEP are bone marrow or hematopoietic stem cell transplantation. Both are linked to high morbidity and mortality rates and must be carefully evaluated. The most significant tool of illness treatment for people who do not undergo transplants is avoiding sun and light exposure. Moreover, patients with severe hemolysis may require frequent blood transfusions. Every two to four weeks, transfusions can reduce photosensitivity by suppressing erythropoiesis and lowering porphyrin synthesis. Such therapy is likely beneficial if the patient's hematocrit remains over 35%, and they can take chelators for the iron overload. Therefore, various treatment approaches are under investigation, including genetically modified hematopoietic stem cells and proteasome inhibitors. Thus, the market is expected to drive in the forecast period from the above statements.Restraint:The high cost of the treatment, stringent reimbursement policies for porphyrias treatment and side effects of the drugs are some factors the market is expected to hamper in the forecast period.<h3>COVID-19 Impact Analysis</h3>The COVID-19 pandemic has moderately impacted healthcare systems and the market. Porphyrins interacted with SARS-COV-2 viral proteins. SARS-COV-2 viruses can generate heme from porphobilinogen and encode all necessary enzymes. Heme-binding sites are found in both E and ORF3a. The heme-iron binding sites were ORF3a's Arg134 and E's Cys44. Human cytochrome C reductase and bacterial EFeB protein had homologous domains in ORF3a. Porphyrin was coupled with the SARS-CoV-2 virus protein to create superior survivability, transmission, and attack power. The majority of porphyrin molecules are hydrophobic and agglomerate in water. The more hydrophobic porphyrin photosensitizer can penetrate mammalian cell membranes. Porphyrin diffuses through the phospholipid bilayer membrane and accumulates in the cytoplasm due to the concentration gradient. SARS-CoV-2 proteins may conduct a series of activities by binding porphyrins. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all HCPs (90 percent) used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.<h3>Segment Analysis:</h3>The medications segment is expected to hold the largest market share in the porphyria treatment market<h3>By Disease Type:</h3><ul><li>Acute Porphyrias<ul style="list-style-type:circle;"><li>Acute Intermittent Porphyria (AIP)</li><li>Hereditary Coproporphyria (HCP)</li><li>Variegate Porphyria (VP)</li><li>ALAD-Deficiency Porphyria (ADP)</li><li>Others</li></ul></li><li>Cutaneous Porphyrias<ul style="list-style-type:circle;"><li>Porphyria Cutanea Tarda (PCT)</li><li>Erythropoietic Protoporphyria (EPP)</li><li>X-Linked Protoporphyria (XLP)</li><li>Congenital Erythropoietic Porphyria (CEP)</li><li>Hepatoerythropoietic Porphyria (HEP)</li><li>Others</li></ul></li></ul><h3>By Diagnosis:</h3><ul><li>Blood test</li><li>Urine test</li><li>Genetic test</li><li>Others</li></ul><h3>By Treatment:</h3><ul><li>Medications<ul style="list-style-type:circle;"><li>Panhematin</li><li>GIVLAARI</li><li>SCENESSE</li><li>Hydroxychloroquine (Plaquenil)</li><li>Chloroquine (Aralen)</li><li>Others</li></ul></li><li>Phlebotomy</li><li>Others</li></ul><h3>By End-user:</h3><ul><li>Hospitals</li><li>Blood Centers</li><li>Others</li></ul><h3>By Distribution Channel:</h3><ul><li>Hospital Pharmacies</li><li>Retail Pharmacies</li><li>Online Pharmacies</li><li>Others</li></ul>The medications segment is expected to dominate in 2021. Acute porphyria attacks are treated by focusing on treating symptoms quickly and preventing consequences. The treatment includes injections of hemin, a medication that is a form of heme, to limit the body's production of porphyrins, intravenous sugar (glucose), or sugar taken by mouth, if able, to maintain an adequate intake of carbohydrates.Moreover, in 2019, the <a target="_blank" rel="noopener noreferrer" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-givosiran-acute-hepatic-porphyria">FDA</a> approved givosiran (Givlaari) as a monthly injection for adults with acute hepatic porphyria to reduce the number of porphyria attacks. Additionally, Taking hydroxychloroquine (Plaquenil) or, less commonly, chloroquine (Aralen), a malaria medicine, helps absorb extra porphyrins and assists your body get rid of them more quickly than usual. Only patients who cannot endure phlebotomy have been prescribed these drugs. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.<h3>Geographical Analysis</h3>North America region holds the largest market share in the global porphyria treatment marketIn 2021, North America accounted for the highest revenue share. The high prevalence of diseases, favorable reimbursement policies, awareness of the disease among people and FDA approvals for the products in the region are factors the market is expected to boost in the forecast period. For instance, according to the American Porphyria Foundation, Porphyria Awareness Week takes place from April 2 to April 9, 2022. Patients are invited to raise awareness in their local communities during this week while participating in various community-building initiatives. For patient-driven awareness and fund-raising efforts, the APF will provide educational materials for their physicians and other medical professionals and the general public.Moreover, GIVLAARI (givosiran) injection for subcutaneous use to treat people with acute hepatic porphyria was approved by the United States Food and Drug Administration in November 2019. (AHP). Therefore, it has increased the demand for the treatment. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.<h3>Competitive Landscape</h3>Major key players in the porphyria treatment market are Recordati Rare Diseases Inc., AmerisourceBergen Corporation, Alnylam Pharmaceuticals, Inc., CLINUVEL PHARMACEUTICALS LTD, sanofi-aventis U.S. LLC, Concordia Pharmaceuticals Inc., AdvaCare Pharma, AuroMedics Pharma LLC.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recordati Rare Diseases Inc.:Overview:RRD (Recordati Rare Disorders Inc.) provides treatments for rare diseases. RRD is part of the Recordati Group, which comprises firms such as Recordati S.p.A. and Orphan Europe, among others. The Recordati Group, founded in 1926, now employs over 4,000 people worldwide. The RRD aims to provide desperately needed medicines to those suffering from highly uncommon and deadly diseases. Moreover, it collaborates with rare disease communities to raise awareness, enhance diagnosis, and increase treatment options for people living with rare diseases.­Product Portfolio:PANHEMATIN: PANHEMATIN is a hemin for injection indicated to ameliorate recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women after initial carbohydrate therapy is known or suspected to be inadequate.

<ol><li>Methodology and Scope<ol><li>Research Methodology</li><li>Research Objective and Scope of the Report</li></ol></li><li>Market Definition and Overview</li><li>Executive Summary<ol><li>Market Snippet by Disease Type</li><li>Market Snippet by Diagnosis</li><li>Market Snippet by Treatment</li><li>Market Snippet by End user</li><li>Market Snippet by Distribution channel</li><li>Market Snippet by Region</li></ol></li><li>Market Dynamics<ol><li>Market Impacting Factors<ol><li>Drivers<ol><li>Advancement in treating congenital Erythropoietic Porphyria is expected to drive market growth.</li></ol></li><li>Restraints:<ol><li>The high cost of the treatment is expected to hamper in the forecast period.</li></ol></li><li>Opportunity</li><li>Impact Analysis</li></ol></li></ol></li><li>Industry Analysis<ol><li>Supply Chain Analysis</li><li>Pricing Analysis</li><li>Unmet Needs</li></ol></li><li>COVID-19 Analysis<ol><li>Analysis of Covid-19 on the Market<ol><li>Before COVID-19 Market Scenario</li><li>Present COVID-19 Market Scenario</li><li>After COVID-19 or Future Scenario</li></ol></li><li>Pricing Dynamics Amid Covid-19</li><li>Demand-Supply Spectrum</li><li>Government Initiatives Related to the Market During Pandemic</li><li>Manufacturers Strategic Initiatives</li><li>Conclusion </li></ol></li><li>By Disease Type<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li><li>Market Attractiveness Index, By Disease Type Segment</li></ol></li><li>Acute Porphyrias*<ol><li>Acute Intermittent Porphyria (AIP)</li><li>Hereditary Coproporphyria (HCP)</li><li>Variegate Porphyria (VP)</li><li>ALAD-Deficiency Porphyria (ADP)</li><li>Others</li><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>Cutaneous Porphyrias<ol><li>Porphyria Cutanea Tarda (PCT)</li><li>Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)</li><li>Congenital Erythropoietic Porphyria (CEP)</li><li>Hepatoerythropoietic Porphyria (HEP)</li><li>Others</li></ol></li></ol></li><li>By Diagnosis<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li><li>Market Attractiveness Index, By Diagnosis Segment</li></ol></li><li>Blood test*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>Urine test</li><li>Genetic test</li><li>Others</li></ol></li><li>By Treatment<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li><li>Market Attractiveness Index, By Treatment Segment</li></ol></li><li>Medications*<ol><li>Panhematin</li><li>GIVLAARI</li><li>SCENESSE</li><li>Hydroxychloroquine (Plaquenil)</li><li>Chloroquine (Aralen)</li><li>Others</li><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>Phlebotomy</li><li>Others</li></ol></li><li>By End-user<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li><li>Market Attractiveness Index, By End user Segment</li></ol></li><li>Hospitals*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>Blood Centers</li><li>Others</li></ol></li><li>By Distribution Channel<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li><li>Market Attractiveness Index, By Distribution Channel Segment</li></ol></li><li>Hospital Pharmacies*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>Retail Pharmacies</li><li>Online Pharmacies</li><li>Others</li></ol></li><li>By Region<ol><li>Introduction<ol><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li><li>Market Attractiveness Index, By Region</li></ol></li><li>North America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>U.S.</li><li>Canada</li><li>Mexico</li></ol></li></ol></li><li>Europe<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>Germany</li><li>U.K.</li><li>France</li><li>Italy</li><li>Spain</li><li>Rest of Europe</li></ol></li></ol></li><li>South America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>Brazil</li><li>Argentina</li><li>Rest of South America</li></ol></li></ol></li><li>Asia Pacific<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>China</li><li>India</li><li>Japan</li><li>Australia</li><li>Rest of Asia Pacific</li></ol></li></ol></li><li>Middle East and Africa<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution&nbsp; Channel</li></ol></li></ol></li><li>Competitive Landscape<ol><li>Key Developments and Strategies</li><li>Company Share Analysis</li><li>Product Benchmarking</li><li>List of Key Companies to Watch</li></ol></li><li>Company Profiles<ol><li>Recordati Rare Diseases Inc.<ol><li>Company Overview</li><li>Product Portfolio and Description</li><li>Key Highlights</li><li>Financial Overview</li></ol></li><li>AmerisourceBergen Corporation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </li><li>Alnylam Pharmaceuticals, Inc.</li><li>CLINUVEL PHARMACEUTICALS LTD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </li><li>sanofi-aventis U.S. LLC </li><li>Concordia Pharmaceuticals Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </li><li>AdvaCare Pharma</li><li>AuroMedics Pharma LLC(*LIST NOT EXHAUSTIVE)</li></ol></li><li>DataM Intelligence<ol><li>Appendix</li><li>About Us and Applications</li><li>Contact Us</li></ol></li></ol>

List of TablesTable1 Global Porphyria Treatment Market Value, By Disease Type, 2021, 2025 &amp; 2029 ($ Million)Table2 Global Porphyria Treatment Market Value, By Diagnosis, 2021, 2025 &amp; 2029 ($ Million)Table3 Global Porphyria Treatment Market Value, By Treatment, 2021, 2025 &amp; 2029 ($ Million)Table4 Global Porphyria Treatment Market Value, By End user, 2021, 2025 &amp; 2029 ($ Million)Table5 Global Porphyria Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)Table6 Global Porphyria Treatment Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)Table7 Global Porphyria Treatment Market Value, By Disease Type, 2021, 2025 &amp; 2029 ($ Million)Table8 Global Porphyria Treatment Market Value, By Disease Type, 2020-2029 ($ Million)Table9 Global Porphyria Treatment Market Value, By Diagnosis, 2021, 2025 &amp; 2029 ($ Million)Table10 Global Porphyria Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)Table11 Global Porphyria Treatment Market Value, By Treatment, 2021, 2025 &amp; 2029 ($ Million)Table12 Global Porphyria Treatment Market Value, By Treatment, 2020-2029 ($ Million)Table13 Global Porphyria Treatment Market Value, By End user, 2021, 2025 &amp; 2029 ($ Million)Table14 Global Porphyria Treatment Market Value, By End user, 2020-2029 ($ Million)Table15 Global Porphyria Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)Table16 Global Porphyria Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)Table17 Global Porphyria Treatment Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)Table18 Global Porphyria Treatment Market Value, By Region, 2020-2029 ($ Million)Table19 North America Porphyria Treatment Market Value, By Disease Type, 2020-2029 ($ Million)Table20 North America Porphyria Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)Table21 North America Porphyria Treatment Market Value, By Treatment, 2020-2029 ($ Million)Table22 North America Porphyria Treatment Market Value, By End user, 2020-2029 ($ Million)Table23 North America Porphyria Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)Table24 North America Porphyria Treatment Market Value, By Country, 2020-2029 ($ Million)Table25 South America Porphyria Treatment Market Value, By Disease Type, 2020-2029 ($ Million)Table26 South America Porphyria Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)Table27 South America Porphyria Treatment Market Value, By Treatment, 2020-2029 ($ Million)Table28 South America Porphyria Treatment Market Value, By End user, 2020-2029 ($ Million)Table29 South America Porphyria Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)Table30 South America Porphyria Treatment Market Value, By Country, 2020-2029 ($ Million)Table31 Europe Porphyria Treatment Market Value, By Disease Type, 2020-2029 ($ Million)Table32 Europe Porphyria Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)Table33 Europe Porphyria Treatment Market Value, By Treatment, 2020-2029 ($ Million)Table34 Europe Porphyria Treatment Market Value, By End user, 2020-2029 ($ Million)Table35 Europe Porphyria Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)Table36 Europe Porphyria Treatment Market Value, By Country, 2020-2029 ($ Million)Table37 Asia-Pacific Porphyria Treatment Market Value, By Disease Type, 2020-2029 ($ Million)Table38 Asia-Pacific Porphyria Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)Table39 Asia-Pacific Porphyria Treatment Market Value, By Treatment, 2020-2029 ($ Million)Table40 Asia-Pacific Porphyria Treatment Market Value, By End user, 2020-2029 ($ Million)Table41 Asia-Pacific Porphyria Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)Table42 Asia-Pacific Porphyria Treatment Market Value, By Country, 2020-2029 ($ Million)Table43 Middle East &amp; Africa Porphyria Treatment Market Value, By Disease Type, 2020-2029 ($ Million)Table44 Middle East &amp; Africa Porphyria Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)Table45 Middle East &amp; Africa Porphyria Treatment Market Value, By Treatment, 2020-2029 ($ Million)Table46 Middle East &amp; Africa Porphyria Treatment Market Value, By End user, 2020-2029 ($ Million)Table47 Middle East &amp; Africa Porphyria Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)Table48 Recordati Rare Diseases Inc.: OverviewTable49 Recordati Rare Diseases Inc.: Product PortfolioTable50 Recordati Rare Diseases Inc.: Key DevelopmentsTable51 AmerisourceBergen Corporation: OverviewTable52 AmerisourceBergen Corporation: Product PortfolioTable53 AmerisourceBergen Corporation: Key DevelopmentsTable54 Alnylam Pharmaceuticals, Inc.: OverviewTable55 Alnylam Pharmaceuticals, Inc.: Product PortfolioTable56 Alnylam Pharmaceuticals, Inc.: Key DevelopmentsTable57 CLINUVEL PHARMACEUTICALS LTD: OverviewTable58 CLINUVEL PHARMACEUTICALS LTD: Product PortfolioTable59 CLINUVEL PHARMACEUTICALS LTD: Key DevelopmentsTable60 sanofi-aventis U.S. LLC: OverviewTable61 sanofi-aventis U.S. LLC: Product PortfolioTable62 sanofi-aventis U.S. LLC: Key DevelopmentsTable63 Concordia Pharmaceuticals Inc.: OverviewTable64 Concordia Pharmaceuticals Inc.: Product PortfolioTable65 Concordia Pharmaceuticals Inc.: Key DevelopmentsTable66 AdvaCare Pharma: OverviewTable67 AdvaCare Pharma: Product PortfolioTable68 AdvaCare Pharma: Key DevelopmentsTable69 AuroMedics Pharma LLC: OverviewTable70 AuroMedics Pharma LLC: Product PortfolioTable71 AuroMedics Pharma LLC: Key DevelopmentsList of FiguresFigure1 Global Porphyria Treatment Market Share, By Disease Type, 2020 &amp; 2029 (%)Figure2 Global Porphyria Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)Figure3 Global Porphyria Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)Figure4 Global Porphyria Treatment Market Share, By End user, 2020 &amp; 2029 (%)Figure5 Global Porphyria Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)Figure6 Global Porphyria Treatment Market Share, By Region, 2020 &amp; 2029 (%)Figure7 Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure8 Global Porphyria Treatment Market Y-o-Y Growth, By Disease Type, 2020-2028 (%)Figure9 Acute Porphyrias: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure10 Cutaneous Porphyrias: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure11 Others: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure12 Global Porphyria Treatment Market Y-o-Y Growth, By Diagnosis, 2020-2028 (%)Figure13 Blood test: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure14 Urine test: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure15 Genetic test: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure16 Others: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure17 Global Porphyria Treatment Market Y-o-Y Growth, By Treatment, 2020-2028 (%)Figure18 Medications: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure19 Phlebotomy: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure20 Others: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure21 Global Porphyria Treatment Market Y-o-Y Growth, By End user, 2020-2028 (%)Figure22 Hospital: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure23 Blood Centers: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure24 Others: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure25 Global Porphyria Treatment Market Y-o-Y Growth, By Distribution Channel, 2020-2028 (%)Figure26 Hospital Pharmacies: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure27 Retail Pharmacies: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure28 Online Pharmacies: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure29 Others: Global Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure30 Global Porphyria Treatment Market Y-o-Y Growth, By Region, 2020-2028 (%)Figure31 North America Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure32 North America Porphyria Treatment Market Share, By Disease Type, 2020 &amp; 2029 (%)Figure33 North America Porphyria Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)Figure34 North America Porphyria Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)Figure35 North America Porphyria Treatment Market Share, By End user, 2020 &amp; 2029 (%)Figure36 North America Porphyria Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)Figure37 North America Porphyria Treatment Market Share, By Country, 2020 &amp; 2029 (%)Figure38 South America Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure39 South America Porphyria Treatment Market Share, By Disease Type, 2020 &amp; 2029 (%)Figure40 South America Porphyria Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)Figure41 South America Porphyria Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)Figure42 South America Porphyria Treatment Market Share, By End user, 2020 &amp; 2029 (%)Figure43 South America Porphyria Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)Figure44 South America Porphyria Treatment Market Share, By Country, 2020 &amp; 2029 (%)Figure45 Europe Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure46 Europe Porphyria Treatment Market Share, By Disease Type, 2020 &amp; 2029 (%)Figure47 Europe Porphyria Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)Figure48 Europe Porphyria Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)Figure49 Europe Porphyria Treatment Market Share, By End user, 2020 &amp; 2029 (%)Figure50 Europe Porphyria Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)Figure51 Europe Porphyria Treatment Market Share, By Country, 2020 &amp; 2029 (%)Figure52 Asia-Pacific Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure53 Asia-Pacific Porphyria Treatment Market Share, By Disease Type, 2020 &amp; 2029 (%)Figure54 Asia-Pacific Porphyria Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)Figure55 Asia-Pacific Porphyria Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)Figure56 Asia-Pacific Porphyria Treatment Market Share, By End user, 2020 &amp; 2029 (%)Figure57 Asia-Pacific Porphyria Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)Figure58 Asia-Pacific Porphyria Treatment Market Share, By Country, 2020 &amp; 2029 (%)Figure59 Middle East &amp; Africa Porphyria Treatment Market Value, 2020-2029 ($ Million)Figure60 Middle East &amp; Africa Porphyria Treatment Market Share, By Disease Type, 2020 &amp; 2029 (%)Figure61 Middle East &amp; Africa Porphyria Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)Figure62 Middle East &amp; Africa Porphyria Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)Figure63 Middle East &amp; Africa Porphyria Treatment Market Share, By End user, 2020 &amp; 2029 (%)Figure64 Middle East &amp; Africa Porphyria Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)Figure65 Recordati Rare Diseases Inc.: FinancialsFigure66 AmerisourceBergen Corporation: FinancialsFigure67 Alnylam Pharmaceuticals, Inc.: FinancialsFigure68 CLINUVEL PHARMACEUTICALS LTD: FinancialsFigure69 sanofi-aventis U.S. LLC: FinancialsFigure70 Concordia Pharmaceuticals Inc.: FinancialsFigure71 AdvaCare Pharma: FinancialsFigure72 AuroMedics Pharma LLC: Financials